Wan-JenHongMD

Hematologic Oncology

Physician

Dr. Hong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2009 - 2012
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2007 - 2010
Stanford University School of MedicineClass of 2007

PubMed

2 citations
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
Marina Y Konopleva, Monique Dail, Naval G Daver, Jacqueline S Garcia, Brian A Jonas
Clinical Lymphoma, Myeloma & Leukemia. 2024-06-01
46 citations
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Naval G Daver, Monique Dail, Jacqueline S Garcia, Brian A Jonas, Karen W L Yee
Blood. 2023-03-16
RWD-derived response in multiple myeloma.
Tao Xu, James Roose, Mellissa Williamson, Ahmed Sawas, Wan-Jen Hong
Plos One. 2023-01-01

Journal Articles

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Courtney D Dinardo, Brian A Jonas, Jacqueline S Garcia, Anthony Letai, Wan-Jen Hong, Keith W Pratz, The New England Journal of Medicine

Abstracts/Posters

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
Wan-Jen Hong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
Wan-Jen Hong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based TherapiesClinically Relevant Abstract
Wan-Jen Hong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b StudyClinically Relevant Abstract
Wan-Jen Hong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia
Wan-Jen Hong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple My...
Wan-Jen Hong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Join now to see all

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021December 11th, 2021
Two Months After Inking a SPAC Deal, Renovacor Taps New CMO; CureVac Reels in a New Development Chief from Merck KGaAJune 4th, 2021
Imago BioSciences Appoints Wan-Jen Hong, M.D., as Chief Medical OfficerJune 3rd, 2021